Accolade (NASDAQ:ACCD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Accolade (NASDAQ:ACCD) released its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01, Briefing.com reports. Accolade had a negative return on equity of 22.57% and a negative net margin of 24.09%. The company had revenue of $124.80 million for the quarter, compared to the consensus estimate of $123.91 million. During the same quarter last year, the business posted ($0.42) EPS. Accolade’s revenue for the quarter was up 26.1% on a year-over-year basis. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Down 14.1 %

Accolade stock traded down $1.30 during midday trading on Friday, reaching $7.89. The stock had a trading volume of 1,491,193 shares, compared to its average volume of 585,879. Accolade has a 12 month low of $6.33 and a 12 month high of $17.00. The company has a market capitalization of $610.76 million, a P/E ratio of -5.93 and a beta of 2.08. The company has a fifty day moving average price of $9.66 and a two-hundred day moving average price of $9.91. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Several research analysts have commented on the company. Needham & Company LLC cut their target price on Accolade from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Friday. Canaccord Genuity Group cut their target price on Accolade from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a report on Monday, February 26th. Stifel Nicolaus cut their target price on Accolade from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, April 22nd. Finally, Raymond James lifted their target price on Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, January 9th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.